{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:37:47Z","timestamp":1771580267082,"version":"3.50.1"},"reference-count":64,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Econom\u00eda y Competitividad-Instituto de Salud Carlos III","award":["PI18\/00677"],"award-info":[{"award-number":["PI18\/00677"]}]},{"name":"Ministerio de Econom\u00eda y Competitividad-Instituto de Salud Carlos III","award":["CIR2019\/035"],"award-info":[{"award-number":["CIR2019\/035"]}]},{"name":"Ministerio de Econom\u00eda y Competitividad-Instituto de Salud Carlos III","award":["CIR2020\/026"],"award-info":[{"award-number":["CIR2020\/026"]}]},{"name":"Ministerio de Econom\u00eda y Competitividad-Instituto de Salud Carlos III","award":["ISCIII CD21\/00087"],"award-info":[{"award-number":["ISCIII CD21\/00087"]}]},{"name":"Fundaci\u00f3 Acad\u00e8mia de Ci\u00e8ncies M\u00e8diques i de la Salut de Catalunya i de Balears","award":["PI18\/00677"],"award-info":[{"award-number":["PI18\/00677"]}]},{"name":"Fundaci\u00f3 Acad\u00e8mia de Ci\u00e8ncies M\u00e8diques i de la Salut de Catalunya i de Balears","award":["CIR2019\/035"],"award-info":[{"award-number":["CIR2019\/035"]}]},{"name":"Fundaci\u00f3 Acad\u00e8mia de Ci\u00e8ncies M\u00e8diques i de la Salut de Catalunya i de Balears","award":["CIR2020\/026"],"award-info":[{"award-number":["CIR2020\/026"]}]},{"name":"Fundaci\u00f3 Acad\u00e8mia de Ci\u00e8ncies M\u00e8diques i de la Salut de Catalunya i de Balears","award":["ISCIII CD21\/00087"],"award-info":[{"award-number":["ISCIII CD21\/00087"]}]},{"name":"Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed","award":["PI18\/00677"],"award-info":[{"award-number":["PI18\/00677"]}]},{"name":"Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed","award":["CIR2019\/035"],"award-info":[{"award-number":["CIR2019\/035"]}]},{"name":"Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed","award":["CIR2020\/026"],"award-info":[{"award-number":["CIR2020\/026"]}]},{"name":"Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed","award":["ISCIII CD21\/00087"],"award-info":[{"award-number":["ISCIII CD21\/00087"]}]},{"name":"CIBERES","award":["PI18\/00677"],"award-info":[{"award-number":["PI18\/00677"]}]},{"name":"CIBERES","award":["CIR2019\/035"],"award-info":[{"award-number":["CIR2019\/035"]}]},{"name":"CIBERES","award":["CIR2020\/026"],"award-info":[{"award-number":["CIR2020\/026"]}]},{"name":"CIBERES","award":["ISCIII CD21\/00087"],"award-info":[{"award-number":["ISCIII CD21\/00087"]}]},{"name":"Spanish Society of Intensive Care Medicine SEMICYUC","award":["PI18\/00677"],"award-info":[{"award-number":["PI18\/00677"]}]},{"name":"Spanish Society of Intensive Care Medicine SEMICYUC","award":["CIR2019\/035"],"award-info":[{"award-number":["CIR2019\/035"]}]},{"name":"Spanish Society of Intensive Care Medicine SEMICYUC","award":["CIR2020\/026"],"award-info":[{"award-number":["CIR2020\/026"]}]},{"name":"Spanish Society of Intensive Care Medicine SEMICYUC","award":["ISCIII CD21\/00087"],"award-info":[{"award-number":["ISCIII CD21\/00087"]}]},{"name":"Sara Borrell grant","award":["PI18\/00677"],"award-info":[{"award-number":["PI18\/00677"]}]},{"name":"Sara Borrell grant","award":["CIR2019\/035"],"award-info":[{"award-number":["CIR2019\/035"]}]},{"name":"Sara Borrell grant","award":["CIR2020\/026"],"award-info":[{"award-number":["CIR2020\/026"]}]},{"name":"Sara Borrell grant","award":["ISCIII CD21\/00087"],"award-info":[{"award-number":["ISCIII CD21\/00087"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with COVID-19 may complicate their evolution with thromboembolic events. Incidence of thromboembolic complications are high and also, patients with the critically-ill disease showed evidence of microthrombi and microangiopathy in the lung probably due to endothelial damage by directly and indirectly injured endothelial and epithelial cells. Pulmonary embolism, deep venous thrombosis and arterial embolism were reported in patients with COVID-19, and several analytical abnormal coagulation parameters have been described as well. D-dimer, longer coagulation times and lower platelet counts have been associated with poor outcomes. The use of anticoagulation or high doses of prophylactic heparin is controversial. Despite the use of anticoagulation or high prophylactic dose of heparin have been associated with better outcomes in observational studies, only in patients with non-critically ill disease benefits for anticoagulation was observed. In critically-ill patient, anticoagulation was not associated with better outcomes. Other measures such as antiplatelet therapy, fibrinolytic therapy or nebulized anticoagulants are being studied in ongoing clinical trials.<\/jats:p>","DOI":"10.3390\/jcm11102695","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T08:31:55Z","timestamp":1652171515000},"page":"2695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anticoagulant Treatment in Severe ARDS COVID-19 Patients"],"prefix":"10.3390","volume":"11","author":[{"given":"Adrian","family":"Ceccato","sequence":"first","affiliation":[{"name":"Critical Care Research Center, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, ParcTaul\u00ed, 08208 Sabadell, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, 41092 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-5324","authenticated-orcid":false,"given":"Marta","family":"Camprub\u00ed-Rimblas","sequence":"additional","affiliation":[{"name":"Critical Care Research Center, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, ParcTaul\u00ed, 08208 Sabadell, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, 41092 Madrid, Spain"},{"name":"Bioscience and Medicine Faculty, Universitat Aut\u00f2noma de Barcelona, Bellaterra, 08193 Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Campa\u00f1a-Duel","sequence":"additional","affiliation":[{"name":"Critical Care Research Center, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, ParcTaul\u00ed, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Areny-Balaguer\u00f3","sequence":"additional","affiliation":[{"name":"Critical Care Research Center, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, ParcTaul\u00ed, 08208 Sabadell, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Morales-Quinteros","sequence":"additional","affiliation":[{"name":"Critical Care Research Center, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, ParcTaul\u00ed, 08208 Sabadell, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, 41092 Madrid, Spain"},{"name":"Bioscience and Medicine Faculty, Universitat Aut\u00f2noma de Barcelona, Bellaterra, 08193 Catalunya, Spain"},{"name":"Department of Intensive Care Medicine, Hospital Universitari Sant Pau, 08025 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-1017","authenticated-orcid":false,"given":"Antonio","family":"Artigas","sequence":"additional","affiliation":[{"name":"Critical Care Research Center, Institut d\u2019Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed I3PT, ParcTaul\u00ed, 08208 Sabadell, Spain"},{"name":"CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, 41092 Madrid, Spain"},{"name":"Bioscience and Medicine Faculty, Universitat Aut\u00f2noma de Barcelona, Bellaterra, 08193 Catalunya, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis","volume":"4","author":"Nopp","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment","volume":"97","author":"Parasher","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe Sepsis and Septic Shock","volume":"369","author":"Angus","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/M20-2566","article-title":"Pulmonary Arterial Thrombosis in COVID-19 with Fatal Outcome: Results from a Prospective, Single-Center, Clinicopathologic Case Series","volume":"173","author":"Lax","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","article-title":"Nebulised heparin as a treatment for COVID-19: Scientific rationale and a call for randomised evidence","volume":"24","author":"Page","year":"2020","journal-title":"Crit. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1016\/S2352-3026(20)30216-7","article-title":"Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study","volume":"7","author":"Goshua","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Iba, T., Warkentin, T.E., Thachil, J., Levi, M., and Levy, J.H. (2021). Proposal of the Definition for COVID-19-Associated Coagulopathy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020191"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"200240","DOI":"10.1183\/16000617.0240-2020","article-title":"Targeting coagulation activation in severe COVID-19 pneumonia: Lessons from bacterial pneumonia and sepsis","volume":"29","author":"Williams","year":"2020","journal-title":"Eur. Respir. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Chi, G., Lee, J.J., Jamil, A., Gunnam, V., Najafi, H., Memar Montazerin, S., Shojaei, F., and Marszalek, J. (2020). Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082489"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tufano, A., Rendina, D., Abate, V., Casoria, A., Marra, A., Buonanno, P., Galletti, F., Di Minno, G., Servillo, G., and Vargas, M. (2021). Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10214925"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"767074","DOI":"10.3389\/fcvm.2021.767074","article-title":"Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan","volume":"8","author":"Oba","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jvs.2020.07.089","article-title":"Early experience with arterial thromboembolic complications in patients with COVID-19","volume":"73","author":"Indes","year":"2021","journal-title":"J. Vasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2021.11.029","article-title":"Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis","volume":"209","author":"Zuin","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s13054-020-03260-3","article-title":"Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: A multicentre observational study","volume":"24","author":"Shah","year":"2020","journal-title":"Crit. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/ejh.13501","article-title":"COVID-19 coagulopathy: An in-depth analysis of the coagulation system","volume":"105","author":"Monsalvo","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e805","DOI":"10.1097\/CCM.0000000000004472","article-title":"Incidence of Venous Thromboembolism in Critically Ill Coronavirus Disease 2019 Patients Receiving Prophylactic Anticoagulation","volume":"48","author":"Trigonis","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"785738","DOI":"10.3389\/fcvm.2021.785738","article-title":"Fundamentals in COVID-19-Associated Thrombosis: Molecular and Cellular Aspects","volume":"8","author":"Mizurini","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jth.14850","article-title":"Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis","volume":"18","author":"Panigada","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc2013656","article-title":"Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with COVID-19","volume":"383","author":"Bowles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","article-title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis","volume":"506","author":"Lippi","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"104362","DOI":"10.1016\/j.jcv.2020.104362","article-title":"Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past","volume":"127","author":"Giannis","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13054-021-03727-x","article-title":"The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients","volume":"25","author":"Torres","year":"2021","journal-title":"Crit. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/postgradmedj-2021-139923","article-title":"Anticoagulation in COVID-19: Current concepts and controversies","volume":"98","author":"Chandra","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1160\/TH07-01-0006","article-title":"The role of heparin and allied compounds in the treatment of sepsis","volume":"98","author":"Cornet","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0950-3536(05)80015-0","article-title":"Mechanism of heparin action","volume":"3","author":"Jackson","year":"1990","journal-title":"Baillieres Clin. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2141.2005.05953.x","article-title":"Guidelines on the use and monitoring of heparin","volume":"133","author":"Baglin","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/atm.2018.01.08","article-title":"Anticoagulant therapy in acute respiratory distress syndrome","volume":"6","author":"Artigas","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"n311","DOI":"10.1136\/bmj.n311","article-title":"Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study","volume":"372","author":"Rentsch","year":"2021","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/M20-6739","article-title":"Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients with COVID-19","volume":"174","author":"Gupta","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12959-021-00337-z","article-title":"Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19","volume":"19","author":"Hamilton","year":"2021","journal-title":"Thromb. J."},{"key":"ref_36","unstructured":"INSPIRATION Investigators (2021). Effect of Intermediate-Dose vs. Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA, 325, 1620\u20131630."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and Safety of Therapeutic-Dose Heparin vs. Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients with COVID-19: The HEP-COVID Randomized Clinical Trial","volume":"181","author":"Spyropoulos","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"REMAP-CAP Investigators, ACTIV-4a Investigators, and ATTACC Investigators (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with COVID-19. N. Engl. J. Med., 385, 777\u2013789.","DOI":"10.1056\/NEJMoa2103417"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"ATTACC Investigators, ACTIV-4a Investigators, and REMAP-CAP Investigators (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N. Engl. J. Med., 385, 790\u2013802.","DOI":"10.1056\/NEJMoa2105911"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jiac.2021.11.008","article-title":"The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials","volume":"28","author":"Kow","year":"2022","journal-title":"J. Infect. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e12638","DOI":"10.1002\/rth2.12638","article-title":"Randomized trials of therapeutic heparin for COVID-19: A meta-analysis","volume":"5","author":"Sholzberg","year":"2021","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ortega-Paz, L., Galli, M., Capodanno, D., Franchi, F., Rollini, F., Bikdeli, B., Mehran, R., Montalescot, G., Gibson, C.M., and Lopes, R.D. (2021). Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. Cardiovasc. Pharmacother., pvab070.","DOI":"10.1093\/ehjcvp\/pvab070"},{"key":"ref_45","unstructured":"RECOVERY Collaborative Group (2022). Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet, 399, 143\u2013151."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jama.2021.23605","article-title":"Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients with COVID-19: A Randomized Clinical Trial","volume":"327","author":"Berger","year":"2022","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e12669","DOI":"10.1002\/rth2.12669","article-title":"MUlticenter study of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study","volume":"6","author":"Barrett","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.chest.2021.09.024","article-title":"Study of Alteplase for Respiratory Failure in SARS-CoV-2 COVID-19: A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized Controlled Trial","volume":"161","author":"Barrett","year":"2022","journal-title":"CHEST"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/cc6894","article-title":"A phase 1 trial of nebulised heparin in acute lung injury","volume":"12","author":"Dixon","year":"2008","journal-title":"Crit. Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/cc9269","article-title":"Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit. Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/cc9286","article-title":"Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: A randomized controlled trial","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit. Care"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-2600(20)30470-7","article-title":"Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: A multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"9","author":"Dixon","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1745-6215-15-91","article-title":"HEPBURN\u2014Investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: Study protocol for a multi-center randomized controlled trial","volume":"15","author":"Glas","year":"2014","journal-title":"Trials"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13613-016-0138-4","article-title":"Nebulized heparin for patients under mechanical ventilation: An individual patient data meta-analysis","volume":"6","author":"Glas","year":"2016","journal-title":"Ann. Intensive Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcrc.2016.04.005","article-title":"Is Inhaled Prophylactic Heparin Useful for Prevention and Management of Pneumonia in Ventilated ICU Patients? The IPHIVAP Investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group","volume":"34","author":"Bandeshe","year":"2016","journal-title":"J. Crit. Care"},{"key":"ref_56","unstructured":"IPHIVAP Investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group (2016). Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients?. J. Crit. Care, 35, 231\u2013239."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4103\/ijccm.IJCCM_183_17","article-title":"A Pilot Study of Nebulized Heparin for Prevention of Ventilator Induced Lung Injury: Comparative Effects with an Inhaled Corticosteroid","volume":"21","author":"Ghiasi","year":"2017","journal-title":"Indian J. Crit. Care Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jth.14685","article-title":"Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats","volume":"18","author":"Puig","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1160\/TH17-05-0347","article-title":"Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury","volume":"117","author":"Chimenti","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Van Haren, F.M.P., van Loon, L.M., Steins, A., Smoot, T.L., Sas, C., Staas, S., Vilaseca, A.B., Barbera, R.A., Vidmar, G., and Beccari, H. (2022). Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients. Br. J. Clin. Pharmacol.","DOI":"10.1111\/bcp.15212"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Van Haren, F.M.P., Laffey, J.G., Artigas, A., Page, C., Schultz, M.J., Cosgrave, D., McNicholas, B., Smoot, T.L., Nunes, Q., and Richardson, A. (2022). Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies. Br. J. Clin. Pharmacol.","DOI":"10.1111\/bcp.15253"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1111\/bcp.14714","article-title":"INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies","volume":"87","author":"Richardson","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s13063-020-04584-9","article-title":"ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A Structured Summary of a Study Protocol for a Randomised Controlled Trial","volume":"21","author":"Wilkinson","year":"2020","journal-title":"Trials"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): An open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:08:50Z","timestamp":1760137730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jcm11102695"],"URL":"https:\/\/doi.org\/10.3390\/jcm11102695","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]}}}